Dyne Therapeutics (DYN) Net Cash Flow (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Net Cash Flow data on file, last reported at -$140.2 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 481.05% year-over-year to -$140.2 million in Q1 2026; TTM through Mar 2026 was $281.3 million, a 40.48% increase from a year earlier, with the FY2025 full-year figure at $458.3 million, up 46.23% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$140.2 million, down from $320.1 million in the prior quarter.
• Over the last five years, Net Cash Flow for DYN reached as high as $336.2 million in Q2 2024 and fell as low as -$140.2 million in Q1 2026.
• Historically, Net Cash Flow has averaged $32.5 million across 5 years, with a median of $8.9 million in 2022.
• On a YoY basis, Net Cash Flow climbed as much as 2589.4% in 2024 and fell as far as 1016.35% in 2024.
• Year by year, Net Cash Flow stood at $27.2 million in 2022, then sank by 131.79% to -$8.7 million in 2023, then plunged by 1016.35% to -$96.7 million in 2024, then soared by 431.01% to $320.1 million in 2025, then sank by 143.81% to -$140.2 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$140.2 million in Q1 2026, $320.1 million in Q4 2025, and $88.6 million in Q3 2025.